These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20878593)

  • 61. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.
    Singh N; Pandey A; Mittal SK
    Expert Rev Mol Med; 2010 Apr; 12():e14. PubMed ID: 20426889
    [TBL] [Abstract][Full Text] [Related]  

  • 62. DNA vaccines against influenza viruses.
    Kim JH; Jacob J
    Curr Top Microbiol Immunol; 2009; 333():197-210. PubMed ID: 19768407
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospects for controlling future pandemics of influenza.
    Robertson JS; Inglis SC
    Virus Res; 2011 Dec; 162(1-2):39-46. PubMed ID: 21963676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Summaries for patients. Assessing the best way to prevent spread of influenza.
    Ann Intern Med; 2009 Dec; 151(12):I31. PubMed ID: 20008744
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.
    Grødeland G; Bogen B
    Expert Rev Vaccines; 2015 Jun; 14(6):805-14. PubMed ID: 25818107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influenza pandemic vaccines: spread them thin?
    Fraser C
    PLoS Med; 2007 Jun; 4(6):e228. PubMed ID: 17579513
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pharmacoeconomic appraisal of the strategy to tackle the H1N1v (A/California/07/09) pandemic in Italy: relevance of the CIRI-IV surveillance system.
    Lai PL; Panatto D; Gasparini R
    J Prev Med Hyg; 2011 Sep; 52(3):142-3. PubMed ID: 22010545
    [No Abstract]   [Full Text] [Related]  

  • 68. Changes in and shortcomings of drug stockpiling, vaccine development and related policies during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans.
    Mei L; Tang Q; Cui YM; Tobe RG; Selotlegeng L; Ali AH; Xu LZ
    Drug Discov Ther; 2013 Jun; 7(3):95-100. PubMed ID: 23917856
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNA-based influenza vaccines as immunoprophylactic agents toward universality.
    Zhang H; El Zowalaty ME
    Future Microbiol; 2016; 11(1):153-64. PubMed ID: 26673424
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A fast track influenza virus vaccine produced in insect cells.
    Cox MM; Hashimoto Y
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S31-41. PubMed ID: 21784229
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity.
    Cooper CL
    Curr Opin Infect Dis; 2012 Feb; 25(1):26-35. PubMed ID: 22183114
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current cell-based influenza vaccine production technology as pandemic contingency.
    Ng SK
    Hum Vaccin Immunother; 2012 Feb; 8(2):267-71. PubMed ID: 22426381
    [No Abstract]   [Full Text] [Related]  

  • 73. The modern crystal ball: influenza forecasting with mathematical models.
    Kansagra SM; Farley TA
    Ann Intern Med; 2009 Dec; 151(12):886-7. PubMed ID: 20008763
    [No Abstract]   [Full Text] [Related]  

  • 74. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia.
    Suhardono M; Ugiyadi D; Nurnaeni I; Emelia I
    Vaccine; 2011 Jul; 29 Suppl 1():A22-5. PubMed ID: 21684423
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.
    Milne G; Kelso J; Kelly H
    J R Soc Interface; 2010 Apr; 7(45):573-86. PubMed ID: 19755499
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat.
    Hampson AW
    Ann Acad Med Singap; 2008 Jun; 37(6):510-7. PubMed ID: 18618064
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Production of adenovirus vectors and their use as a delivery system for influenza vaccines.
    Vemula SV; Mittal SK
    Expert Opin Biol Ther; 2010 Oct; 10(10):1469-87. PubMed ID: 20822477
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
    Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
    Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.
    Hardy S; Eichelberger M; Griffiths E; Weir JP; Wood D; Alfonso C
    Influenza Other Respir Viruses; 2011 Nov; 5(6):438-42. PubMed ID: 21668676
    [No Abstract]   [Full Text] [Related]  

  • 80. Vaccines for pandemic influenza. Preface.
    Compans RW; Orenstein WA
    Curr Top Microbiol Immunol; 2009; 333():v-viii. PubMed ID: 19787865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.